zoledronic acid has been researched along with Jaw Diseases in 143 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 89 (62.24) | 29.6817 |
2010's | 51 (35.66) | 24.3611 |
2020's | 3 (2.10) | 2.80 |
Authors | Studies |
---|---|
Huo, L; Li, JW; Wang, JY; Yu, RQ; Zheng, LW | 1 |
Arce, RM; Auersvald, CM; Awad, ME; Celis, E; Cutler, CW; Elashiry, M; Eldin M Elshikh, M; Elsalanty, ME; Elsayed, R; Gerber, J; Isales, C; Kurago, Z; Meghil, M; Sultan, H; Sun, C; Zeitoun, R | 1 |
Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T | 1 |
Hirasawa, N; Imatoh, T; Sai, K; Saito, Y; Segawa, K; Takeyama, M | 1 |
Beth-Tasdogan, NH; Hussein, H; Mayer, B; Zolk, O | 1 |
Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
Çankaya, M; Dayisoylu, EH; Ersöz, S; Şenel, FÇ; Taskesen, F; Tosun, E; Üngör, C | 1 |
Shapiro, CL | 1 |
Agrawal, R; Bell, R; Brown, JE; Cameron, D; Chakraborti, P; Coleman, RE; Collinson, M; Jyothirmayi, R; Liversedge, V; Marshall, HC; Murden, GA; Rathbone, EJ; Spensley, S; Yuille, F | 1 |
Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Koerdt, S; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
Cha, IH; Kim, JW; Kim, MR; Kim, SJ; Landayan, ME; Lee, JY; Tatad, JC | 1 |
Gallego, L; Junquera, L | 1 |
Andreadis, C; Boukovinas, I; Koloutsos, G; Kyrgidis, A; Patrikidou, A; Teleioudis, Z; Triaridis, S; Vahtsevanos, K | 1 |
Al-Nawas, B; Beck, J; Gamm, H; Grötz, KA; Thomas, C; Thüroff, JW; Wagner, W; Walter, C; Zinser, V | 1 |
Cheng, JC; Wong, YK | 1 |
Ascani, L; Bareggi, C; Brunelli, C; Campa, T; Cislaghi, E; Fagnoni, E; Maniezzo, M; Ripamonti, CI; Saibene, G | 1 |
Bareggi, C; Bianchi, C; Borgonovo, K; Cobelli, S; Farina, G; Garassino, M; La Verde, N; Mantica, C; Mihali, D; Pedretti, D; Perrone, S; Rizzo, A; Sburlati, P | 1 |
Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
Anderson, KC; Lerman, MA; Lyng, GD; Sonis, ST; Watkins, BA | 1 |
Kyrgidis, A; Teleioudis, Z; Vahtsevanos, K | 1 |
Abati, S; Carmagnola, D; Celestino, S | 1 |
Berruti, A; Fusco, V; Ortega, C | 1 |
Badros, A; Chaisuparat, R; Cullen, KJ; Meiller, TF; Scheper, MA | 1 |
Kyrgidis, A; Triaridis, S | 1 |
Andreadis, C; Kyrgidis, A | 1 |
Frerich, B; Hemprich, A; Kluge, R; Sabri, O; Schulz, T; Steinhoff, K; Wilde, F; Winter, K | 1 |
Chantrain, G; Decaestecker, C; Hupin, C; Javadian, R; Loeb, I; Magremanne, M; Saussez, S | 1 |
Ayllon, J; Cros, C; Launay-Vacher, V; Medioni, J; Oudard, S; Spano, JP | 1 |
Biasotto, M; Chiandussi, S; De Nardi, E; Di Lenarda, R; Dore, F; Tirelli, G | 1 |
Kressley, A; Saif, MW; Smith, A | 1 |
Elad, S; Hardan, I; Lazarovici, TS; Taicher, S; Yahalom, R; Yarom, N | 1 |
Balasanian, E; Stanton, DC | 1 |
Fenner, M; Hinkmann, FM; Lell, MM; Neukam, FW; Nkenke, E; Stockmann, P; Vairaktaris, E | 1 |
Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS | 1 |
Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A | 1 |
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
Castellana, MA; Gasparini, G; Longo, R | 1 |
Hata, K; Hiraga, T; Kobayashi, Y; Matsumoto-Nakano, M; Ueda, A; Wang, L; Yatani, H; Yoneda, T | 1 |
Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
Divgi, C; Grewal, RK; Hudis, CA; Larson, S; Mak, AF; Modi, S; Morris, PG; Patil, S; Poznak, CV | 1 |
Fossion, E; Huizing, MT; Van den Wyngaert, T; Vermorken, JB | 1 |
Adams, JS; Christensen, R; Chung, EM; Felsenfeld, AL; Garrett, N; Hokugo, A; Nishimura, I; Sayre, JW; Sung, EC | 1 |
Akiyama, K; Chen, C; Chen, W; Kikuiri, T; Kim, I; Le, AD; Li, Y; Shi, S; Wang, S; Yamaza, T; Zhang, Q | 1 |
Biasotto, M; Cavalli, F; Chiandussi, S; Contardo, L; Di Lenarda, R; Dore, F; Giacca, M; Moimas, S; Pozzato, G; Zacchigna, S; Zanconati, F | 1 |
Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M | 1 |
Allen, MR; Burr, DB; Chu, TM; Kubek, DJ; Ruggiero, SL | 1 |
Bi, Y; Cao, C; Ehirchiou, D; Gao, Y; Kikuiri, T; Le, A; Shi, S; Zhang, L | 1 |
Beninati, F; Ficarra, G | 1 |
Lurie, R; Meer, S; Suleman, YF | 1 |
Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I | 1 |
Bauer, F; Ehrenfeld, M; Hafner, S; Hohlweg-Majert, B; Kolk, A; Kreutzer, K; Mast, G; Otto, S; Pautke, C; Steiner, T; Stürzenbaum, SR; Tischer, T; Weitz, J; Wolff, KD | 1 |
Black, DM; Bucci-Rechtweg, C; Grbic, JT; Lyles, KW; McClung, M; Orwoll, E; Reid, DM; Su, G | 1 |
Acham, S; Jakse, N; Obermayer-Pietsch, B; Rugani, P; Truschnegg, A | 1 |
Berenson, JR; Bolejack, V; Crowley, J; Farber, CM; Flinn, IW; Gravenor, DS; Hilger, JD; Makary, A; Morganstein, N; Nassir, Y; Sanani, S; Sefaradi, A; Shamouelian, A; Staszewski, H; Swift, RA; Tiffany, NM; Upadhyaya, GH; Yang, HH; Yellin, O | 1 |
Liu, Y; Ning, J; Ravosa, MJ; Stack, MS | 1 |
Pazianas, M | 1 |
Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P | 1 |
Díaz-Bobes, C; Gallego, L; Junquera, L; Pelaz, A | 1 |
Arduino, PG; Battaglio, C; Berardi, D; Broccoletti, R; Chiecchio, A; Donadio, M; Gandolfo, S; Menegatti, E; Mozzati, M; Scoletta, M; Scully, C; Vandone, AM | 1 |
Campisi, G; Colella, G; Favia, G; Fusco, V; Gabriele, M; Gaeta, GM; Manfredi, M; Mergoni, G; Merigo, E; Peluso, F; Solazzo, L; Vescovi, P | 1 |
Ferlito, S; Liardo, C; Puzzo, S | 1 |
Amann, K; Hyckel, P; Neukam, F; Nkenke, E; Ries, J; Schlegel, K; Stockmann, P; Wehrhan, F | 1 |
Barrett-Lee, PJ; Bell, R; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Davies, C; Dodwell, D; Gil, M; Grieve, RJ; Houston, SJ; Keane, M; Thorpe, H; Woodward, E | 1 |
Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D | 1 |
Friedlander, AH | 1 |
Bouganim, N; Clemons, M; Finkelman, RD | 1 |
Aapro, MS | 1 |
Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P | 1 |
Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
Angeli, A; Berruti, A; Bertetto, O; Ciccone, G; Ciuffreda, L; Fusco, V; Galassi, C; Ortega, C | 1 |
Baldwin, CM; D'Silva, NJ; Edwards, PC; Feinberg, SE; Krebsbach, PH; Kuo, S; Scheller, EL | 1 |
Barbounis, V; Boziari, P; Karayianni, A; Kyrtsonis, MC; Migliorati, CA; Nicolatou-Galitis, O; Papadopoulou, E; Repousis, P; Sarri, T | 1 |
Amann, K; Guentsch, A; Neukam, FW; Nkenke, E; Schlegel, KA; Stockmann, P; Wehrhan, F; Wehrhan, T | 1 |
Antoniades, K; Arora, A; Kyrgidis, A | 1 |
Frustino, JL; Kossoff, EB; Ngamphaiboon, N; O'Connor, TL; Sullivan, MA | 1 |
Bartl, R | 1 |
Bonacina, R; Mariani, U; Villa, A; Villa, F | 1 |
Arata, V; Gallesio, G; Mozzati, M | 1 |
Basi, DL; Dudek, AZ; Gopalakrishnan, R; Huckabay, S; Hughes, PJ; Leach, JW; Lunos, S; Swenson, KK; Thumbigere-Math, V; Tu, L | 1 |
Uña, E | 1 |
Marx, RE | 1 |
Csermak, K; Tarassoff, P | 1 |
Carter, GD; Goss, AN | 1 |
Greenberg, MS | 1 |
Bagan, JV; Jimenez-Soriano, Y | 1 |
Crowley, J; Durie, BG; Katz, M | 1 |
Hande, K; Richardson, PG; Woo, SB | 1 |
Duck, L; Maerevoet, M; Martin, C | 1 |
Hellie, CM; Olson, KB; Pienta, KJ | 1 |
Bourgeois, SL; Goodell, GG; Sarathy, AP | 1 |
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
Bagan, JV; Diaz, JM; Hernandez, S; Jimenez, Y; Murillo, J; Poveda, R; Sanchis, JM; Scully, C | 1 |
Gibbs, SD; O'Grady, J; Prince, HM; Seymour, JF | 1 |
Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E | 1 |
Abi Najm, S; Carrel, JP; Lesclous, P; Lombardi, T; Lysitsa, S; Samson, J | 1 |
Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C | 1 |
Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T | 1 |
Aglietta, M; Faggiuolo, R; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
Alexander, RE | 1 |
Soileau, KM | 1 |
Farrar, SK | 1 |
Englund, K; Hatch, C; Hussein, MA; Isada, C; Karam, MA; Licata, A; Reed, J; Richmond, M; Smith, J; Thakkar, SG; Tomford, JW | 1 |
Dimitrakopoulos, I; Karakasis, D; Magopoulos, C | 1 |
Anagnostopoulos, A; Bamia, C; Bamias, A; Dimopoulos, MA; Gika, D; Kastritis, E; Melakopoulos, I; Moulopoulos, LA; Terpos, E; Tsionos, K | 1 |
Gregersen, H; Neumann, B | 1 |
Biasotto, M; Cavalli, F; Chiandussi, S; Cova, MA; Di Lenarda, R; Dore, F | 1 |
Weeda, LW | 1 |
Kademani, D; Koka, S; Lacy, MQ; Rajkumar, SV | 1 |
Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A | 1 |
Doyle-Lindrud, S | 1 |
Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA | 1 |
Baccarani, M; Brioli, A; Cangini, D; Catalano, L; Cavo, M; Ceccolini, M; Cellini, C; D'Arco, A; Di Raimondo, F; Offidani, M; Perrone, G; Ronconi, S; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
Calvo-Villas, JM; Carreter de Granda, E; Govantes Rodríguez, J; Sicilia Guillén, F; Tapia Torres, M | 1 |
Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Quintero Pérez, S | 1 |
Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I | 1 |
Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E | 1 |
Agazzi, A; D'Orto, O; Derada Troletti, G; Diego, R; Fontanella, W; Marzano, U; Pagani, D; Pignataro, L | 1 |
Dannemann, C; Grätz, KW; Riener, MO; Zwahlen, RA | 1 |
Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E | 1 |
Corso, A; Klersy, C; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P | 1 |
Arpaci, F; Ataergin, S; Kanat, O; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
Lipton, A | 1 |
Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A | 1 |
Jawad, AS; Shenker, NG | 1 |
Aglietta, M; Faggiuolo, R; Gilardino, MO; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
Ashworth, D; Grew, N; Millar, B; Shetty, S; Srinivasan, D | 1 |
Díaz Rubio, E; García Paredes, B; García Sáenz, JA; López Tarruella, S; Rodríguez Lajusticia, L; Villalobos, L | 1 |
Guthmiller, JM; Humbert, LA; Johnson, GK; Statz, TA | 1 |
Borrás-Blasco, J; Casterá, E; Costa, S; Galan-Brotons, A; Giner-Marco, V; Rosique-Robles, D | 1 |
Casas, N; Delmas, PD; Eriksen, EF; Grbic, JT; Hua, Y; Landesberg, R; Leung, PC; Lin, SQ; Mesenbrink, P; Recknor, CP; Reid, IR | 1 |
Brown, JJ; Ramalingam, L; Zacharin, MR | 1 |
Abu-Id, MH; Acil, Y; Gottschalk, J; Kreusch, T; Russo, PA; Springer, I; Warnke, PH; Wiltfang, J | 1 |
Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A | 1 |
Dodson, TB; Wessel, JH; Zavras, AI | 1 |
Altundag, K; Bulut, N; Sari, E | 1 |
Bagan, JV; Gómez, D; Jiménez, Y; Poveda, R; Scully, C; Sirera, R | 1 |
Moore, S; Reilly, MM | 1 |
De Zorzi, Pde M; Lovat, CP; Reiriz, AB | 1 |
9 review(s) available for zoledronic acid and Jaw Diseases
Article | Year |
---|---|
Interventions for managing medication-related osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Intercellular Signaling Peptides and Proteins; Jaw Diseases; Male; Oral Health; Osteonecrosis; Postoperative Complications; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tooth Extraction; Zoledronic Acid | 2017 |
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandible; Osteonecrosis; Pamidronate; Retrospective Studies; Zoledronic Acid | 2007 |
Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.
Topics: Aged; Bone Density Conservation Agents; Contraindications; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2005 |
Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2006 |
[Bisphosphonate-associated osteonecrosis of the jaw].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Neoplasms; Osteoporosis; Pamidronate; Risk Factors; Zoledronic Acid | 2006 |
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
The safety of zoledronic acid.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Creatinine; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; Product Surveillance, Postmarketing; Zoledronic Acid | 2007 |
10 trial(s) available for zoledronic acid and Jaw Diseases
Article | Year |
---|---|
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Oral Health; Osteonecrosis; Quality of Life; Zoledronic Acid | 2013 |
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow-Up Studies; Gadolinium; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandibular Diseases; Maxillary Diseases; Organometallic Compounds; Osteolysis; Osteonecrosis; Pamidronate; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Middle Aged; Osteonecrosis; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate; Zoledronic Acid | 2010 |
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Databases as Topic; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Osteonecrosis; Osteoporosis, Postmenopausal; Peptides; Placebos; Prevalence; Risk Factors; United States; Zoledronic Acid | 2010 |
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Osteonecrosis; Treatment Outcome; Zoledronic Acid | 2011 |
Tooth extraction in patients on zoledronic acid therapy.
Topics: Case-Control Studies; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Radiography, Panoramic; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid | 2012 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Risk; Time Factors; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Thalidomide; Zoledronic Acid | 2006 |
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Linear Models; Male; Metronidazole; Middle Aged; Osteonecrosis; Pamidronate; Prospective Studies; Zoledronic Acid | 2007 |
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteitis; Osteomyelitis; Osteonecrosis; Osteoporosis, Postmenopausal; Periapical Abscess; Zoledronic Acid | 2008 |
124 other study(ies) available for zoledronic acid and Jaw Diseases
Article | Year |
---|---|
Effects of Soft Tissue Closure on Medication-Related Osteonecrosis of the Jaw in a Rabbit Model with Tooth Extraction: A Pilot Study.
Topics: Animals; Bicuspid; Bone Density; Female; Jaw Diseases; Mandible; Models, Animal; Osteonecrosis; Pilot Projects; Rabbits; Tooth; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2021 |
Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Cell Differentiation; Dendritic Cells; Homeostasis; Imidazoles; Jaw Diseases; Osteoclasts; Osteonecrosis; Tooth Extraction; Wound Healing; Zoledronic Acid | 2020 |
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid | 2022 |
Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Asian People; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Japan; Jaw Diseases; Logistic Models; Odds Ratio; Osteonecrosis; Zoledronic Acid | 2017 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw Diseases; Mandible; Osteogenesis; Osteoporosis; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Tooth Extraction; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective.
Topics: Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2013 |
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Femur; Frontal Bone; Humans; Image Processing, Computer-Assisted; Imidazoles; Jaw Diseases; Mandible; Maxilla; Middle Aged; Osteonecrosis; Radionuclide Imaging; RANK Ligand; Retrospective Studies; Zoledronic Acid | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw Diseases; Microscopy, Electron, Scanning; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Risk Factors; Zoledronic Acid | 2016 |
Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Dental Care for Chronically Ill; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Logistic Models; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Follow-Up Studies; Germany; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prevalence; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Tooth Extraction; Zoledronic Acid | 2008 |
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Topics: Academies and Institutes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandibular Diseases; Maxillary Diseases; Oral Ulcer; Osteonecrosis; Prospective Studies; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2009 |
Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Topics: Bone Density Conservation Agents; Diphosphonates; Disease Progression; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Topics: Aged; Aged, 80 and over; Alveolar Bone Loss; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; DMF Index; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Periodontal Index; Pilot Projects; Retrospective Studies; Risk Factors; Stomatitis, Denture; Tooth Extraction; Zoledronic Acid | 2008 |
Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.
Topics: Apoptosis; Blotting, Western; Bone Density Conservation Agents; Caspase 3; Caspase 9; Cell Line; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Gene Expression; Gene Expression Profiling; Gingiva; Humans; Imidazoles; In Situ Nick-End Labeling; Jaw Diseases; Mouth Mucosa; Oligonucleotide Array Sequence Analysis; Osteonecrosis; RNA Interference; RNA, Small Interfering; Zoledronic Acid | 2009 |
Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2009 |
Clinical characterization might help in preventing osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2008 |
Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Positron-Emission Tomography; Radiopharmaceuticals; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series.
Topics: Adult; Aged; Aged, 80 and over; Belgium; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Topics: Angiogenesis Inhibitors; Diphosphonates; Humans; Imidazoles; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib; Zoledronic Acid | 2009 |
Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2009 |
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Osteonecrosis; Pancreatic Neoplasms; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Minimally Invasive Surgical Procedures; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing; Zoledronic Acid | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Treatment Outcome; Zoledronic Acid | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid | 2010 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and left thumb.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Curettage; Diphosphonates; Female; Finger Phalanges; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Osteotomy; Radiography; Thumb; Zoledronic Acid | 2009 |
Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.
Topics: Animals; Bacterial Adhesion; Bacterial Physiological Phenomena; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Dental Plaque; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Jaw Diseases; Male; Mice; Mice, Inbred Strains; Mouth Mucosa; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; Streptococcus mutans; Tooth Extraction; Tooth Socket; Wound Healing; Zoledronic Acid | 2010 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Risk Factors; Tomography, Emission-Computed; Zoledronic Acid | 2010 |
Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.
Topics: Animals; Apoptosis; Diphosphonates; Disease Models, Animal; Femur; Gene Expression Regulation; Humans; Imidazoles; Inflammation; Jaw Diseases; Oligonucleotide Array Sequence Analysis; Osteoclasts; Osteogenesis; Osteonecrosis; Rats; Rats, Sprague-Dawley; Tooth Extraction; Vitamin D; Vitamin D Deficiency; Zoledronic Acid | 2010 |
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Cytokines; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Immunosuppressive Agents; Immunotherapy; Jaw Diseases; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Nude; Osteonecrosis; T-Lymphocytes, Regulatory; Zoledronic Acid | 2010 |
A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Maxillary Diseases; Osteonecrosis; Radionuclide Imaging; Rats; Rats, Wistar; Reproducibility of Results; Tooth Extraction; Zoledronic Acid | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2010 |
Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.
Topics: Animals; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Dogs; Female; Imidazoles; Jaw Diseases; Osteonecrosis; Tomography, X-Ray Computed; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2011 |
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Remodeling; Dexamethasone; Diphosphonates; Docetaxel; Humans; Imidazoles; Jaw Diseases; Mandible; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Osteocytes; Osteonecrosis; Taxoids; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid | 2010 |
Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Debridement; Diphosphonates; Doxycycline; Female; Fluorescence; Fluorescent Dyes; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pilot Projects; Prospective Studies; Surgical Flaps; Surgical Wound Dehiscence; Treatment Outcome; Wound Healing; Zoledronic Acid | 2011 |
Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Laser Therapy; Lasers, Solid-State; Low-Level Light Therapy; Mandibular Diseases; Middle Aged; Osteonecrosis; Photochemotherapy; Surgical Wound Dehiscence; Wound Healing; Zoledronic Acid | 2010 |
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2011 |
Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts.
Topics: Apoptosis; Cell Line; Cell Movement; Cell Proliferation; Collagen; Diphosphonates; Down-Regulation; Epithelial Cells; Fibroblasts; Humans; Imidazoles; Jaw Diseases; Mouth Mucosa; Osteonecrosis; Reverse Transcriptase Polymerase Chain Reaction; Staining and Labeling; Tooth Extraction; Wound Healing; Zoledronic Acid | 2011 |
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid | 2011 |
Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw?
Topics: Bone Density Conservation Agents; Dental Caries; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Risk Factors; Root Canal Therapy; Rubber Dams; Zoledronic Acid | 2011 |
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Diphosphonates; Female; Haplotypes; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Odds Ratio; Osteonecrosis; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Italy; Jaw Diseases; Male; Middle Aged; Orthognathic Surgical Procedures; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2011 |
Preventive protocol for tooth extractions in patients treated with zoledronate: a case series.
Topics: Antibiotic Prophylaxis; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Radiography, Panoramic; Tooth Extraction; Zoledronic Acid | 2011 |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Remodeling; Cell Count; Diphosphonates; Fibroblasts; Humans; Imidazoles; Immunohistochemistry; Jaw Diseases; MSX1 Transcription Factor; Osteoblasts; Osteocytes; Osteonecrosis; Osteopetrosis; Pamidronate; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Zoledronic Acid | 2011 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw.
Topics: Biomarkers; Bone Density Conservation Agents; Collagen Type I; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Peptides; Risk Factors; Zoledronic Acid | 2011 |
More about osteonecrosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Dental Care; Diphosphonates; Drug Interactions; Humans; Imidazoles; Jaw Diseases; Oral Hygiene; Osteonecrosis; RANK Ligand; Risk Factors; Zoledronic Acid | 2011 |
Denosumab for bone metastases from breast cancer: a new therapy option?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Incidence; Jaw Diseases; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
Bisphosphonates inhibit expression of p63 by oral keratinocytes.
Topics: Adult Stem Cells; Analysis of Variance; Bone Density Conservation Agents; Case-Control Studies; Cell Line, Transformed; Diphosphonates; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Jaw Diseases; Keratinocytes; Membrane Proteins; Mevalonic Acid; Osteonecrosis; RNA, Small Interfering; Tissue Culture Techniques; Wound Healing; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Cariostatic Agents; Chlorhexidine; Dental Prophylaxis; Diphosphonates; Female; Fluorides; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Longitudinal Studies; Male; Middle Aged; Neoplasms; Oral Hygiene; Osteonecrosis; Pain Measurement; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue.
Topics: Alkaline Phosphatase; Alveolar Process; Antigens, CD; Bone Density Conservation Agents; Capillaries; Coloring Agents; Connective Tissue; Diphosphonates; Endoglin; Endothelial Cells; Endothelium, Vascular; Humans; Image Processing, Computer-Assisted; Imidazoles; Immunohistochemistry; Jaw Diseases; Mouth Mucosa; Neovascularization, Physiologic; Osteonecrosis; Periosteum; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Cell Surface; Zoledronic Acid | 2011 |
Rubber dam clamp trauma, root canal therapy, and osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Root Canal Therapy; Rubber Dams; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pamidronate; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid | 2011 |
Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Risk Factors; Zoledronic Acid | 2011 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Neoplasms; Osteonecrosis; Pamidronate; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Zoledronic Acid | 2012 |
Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2012 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Zoledronic Acid | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2003 |
Bisphosphonates and avascular necrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2003 |
Intravenous bisphosphonates and osteonecrosis.
Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Diseases; Osteolysis; Osteonecrosis; Pamidronate; Zoledronic Acid | 2004 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Time Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2005 |
[Bisphosphonates-related jaw osteonecrosis].
Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2006 |
Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Topics: Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Periodontitis; Zoledronic Acid | 2006 |
Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2005 |
The buzz about bisphosphonates.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteomyelitis; Osteonecrosis; Pamidronate; Paraproteinemias; Zoledronic Acid | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Drug induced osteonecrosis of the jaws.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteoclasts; Osteomyelitis; Osteonecrosis; Pamidronate; Splints; Zoledronic Acid | 2006 |
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Oral Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Monitoring; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
[Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis; Radiotherapy; Zoledronic Acid | 2006 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2007 |
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Risk Factors; Switzerland; Time Factors; Zoledronic Acid | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
Bisphosphonate treatment as a cause of jaw osteonecrosis.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Chlorhexidine; Diphosphonates; Facial Pain; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Tetracycline; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mandibular Fractures; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid | 2007 |
Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Time Factors; Zoledronic Acid | 2007 |
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Zoledronic Acid | 2008 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Zoledronic Acid | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Logistic Models; Male; Multivariate Analysis; Neoplasms; Obesity; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Time Factors; Zoledronic Acid | 2008 |
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Case-Control Studies; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Penicillin V; Risk Factors; Tooth Extraction; Zoledronic Acid | 2008 |
Bisphosphonates and osteonecrosis of the jaw: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |